News | April 03, 2022
WHO suspends supply of Covaxin under Covax facility
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy
It would be the first protein-based alternative available in Israel
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
It’s a two-dose vaccine administered 28 days apart
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
Subscribe To Our Newsletter & Stay Updated
